SCHEMBL21597304

SCHEMBL21597304

Cc1nnc(-c2cc(N)n(C)n2)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ ADORA2B P29275 2/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ SYK P43405 2/20 0.31
▸ LRRK2 Q5S007 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ CACNA2D1 P54289 1/20 0.31
▸ GPR84 Q9NQS5 1/20 0.31
▸ BACE1 P56817 3/20 0.30
▸ BACE2 Q9Y5Z0 3/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26051626 0.84 ALDH1A1 (0.34) CA12CA1CA2CA9SYK
SCHEMBL26051625 0.72 KMT2A (0.44) GPR84BACE1BACE2MAPTKMT2A
SCHEMBL15813458 0.71 TSHR (0.39) BACE1BACE2NPC1TP53MAPT
SCHEMBL26067069 0.69 SYK (0.44) CA12CA1CA2CA9SYK
SCHEMBL26195687 0.69 COMT (0.41) CA12CA1CA2CA9LRRK2
SCHEMBL21597332 0.69 — —
SCHEMBL21597748 0.68 BRD4 (0.36) ADORA2BADORA1BACE1BACE2
SCHEMBL10068343 0.66 NOTUM (0.38) CA12CA1CA2CA9GPR84
SCHEMBL25408554 0.66 POLB (0.41) ADORA2BNPC1CYP1A2MAPTRAB9A
SCHEMBL26778349 0.66 CCR1 (0.57) SYKGPR84MEN1NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 — — US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 — — US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 — — US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 — — EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 — — CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 CA12 1917/4885CA1 2121/4885CA2 1144/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 CA12 1917/4885CA1 2121/4885CA2 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback